|
Advisory Committee Recommends Lower Dose of Novartis’ Indacaterol
An FDA advisory committee agreed to recommend approval of a lower dose of Novartis’ chronic obstructive pulmonary disease (COPD) drug indacaterol after finding that a high dosage version didn’t provide any additional benefit.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives